Neumora Therapeutics remains a clinical-stage biotech focused on central nervous system disorders, highlighted by encouraging Phase 1b results for NMRA-511 targeting Alzheimer's disease agitation. Despite ongoing steep net losses nearing $237 million in 2025, the company maintains a robust liquidity position with $183 million in cash and a strong current ratio of 5.87. Neumora's capital structure reflects active management efforts including convertible loan conversions into equity to sustain funding amid the costly clinical development cycle. Investors should closely monitor upcoming clinical readouts and cash runway dynamics given persistent sector risks and financial pressures.